Drug-induced nephropathy: an update

Bibliography

• CLIVE DM, STOFF JS: Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl. J. Med. (1984) 310(9):563–572.
   PubMed Web of Science ®Google Scholar
• •Classic article on NSAID-associated renal syndromes.
   Google Scholar
• SCHLONDORFF D: Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int. (1993) 44:643–653.
   PubMed Web of Science ®Google Scholar
• SMITH WL, DEWITT DL: Biochemistry and prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Sem. Nephrol (1995) 15(3):179–194.
   PubMed Web of Science ®Google Scholar
• CROFFORD LJ: COX-1 and COX-2 Tissue expression: Implications and predictions. Rheumatol (1997) 24\(Suppl. 49):15–19.
   Google Scholar
• KOMHOFF M, GRONE H-J, KLEIN T, SEYBERTH HW, NUSING RM: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am. J. Physiol (1997) 272(Renal Physiol. 41):F460–F468.
   Google Scholar
• ••Important paper revealing localisationof COX enzymes in human kidney.
   Google Scholar
• HAO CM, KOMHOFF M, GUAN Y, REDHA R, BREYER MD: Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial survival. Ain. J. Physiol (1999) 277(Renal Physiol. 46):F352–F359.
   Google Scholar
• HARRIS RC, MCKANNA JA, AKAI Y et al: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest. (1994) 94:2504–2510.
   PubMed Web of Science ®Google Scholar
• FITZPATRICK FA, SOBERMAN R: Regulated formation of eicosanoids. Clin. Invest. (2001) 107:1347–1351.
   Google Scholar
• PERAZELLA MA: COX-2 selective inhibitors: Analysis of renal effects. Expert Opin. Drug Sal (2002) 1:53–64.
   PubMedGoogle Scholar
• PERAZELLA MA, TRAY K: Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am. J. Med. (2001) 111:64–67.
   PubMed Web of Science ®Google Scholar
• ••Important paper describing nephrotoxicityof COX-2 inhibitors.
   Google Scholar
• NANKIVELL BJ, BORROWS RJ, FUNG ALS et al.: Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation (2004) 78:557–565.
   PubMed Web of Science ®Google Scholar
• FELLSTROM B: Cyclosporine nephrotoxicity. Transplantation Proc. (2004) 36:220S–223S.
   Google Scholar
• BUSAUSCHINA A, SCHNUELLE P, VAN DER WOUDE FJ: Cyclosporine nephrotoxicity. Transplantation Proc. (2004) 36:229S–233S.
   Google Scholar
• PAUL LC, DE FIJTER JH: Cyclosporine-induced renal dysfunction. Transplantation Proc. (2004) 36:224S–228S.
   Google Scholar
• NAVAR LG, HARRISON-BERNARD LM, IMIG JD, WANG CT, CERVENKA L, MITCHELL KD: Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J. Am. Soc. Nephrol (1999) 10:S266–S272.
   PubMed Web of Science ®Google Scholar
• BREWSTER UC, PERAZELLA MA: The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease. Am. J. Med. (2004) 116:263–272.
   PubMed Web of Science ®Google Scholar
• PACKER M, LEE WH, MEDINA N et al.: Functional renal insufficiency during long-term therapy with captopril and enalapril in severe congestive heart failure. Ann. Intern. Med. (1987) 106:346–355.
   PubMed Web of Science ®Google Scholar
• FLOMBAUM CD, MOURADIAN JA, CASPER ES, ERLANDSON RA, BENEDETTI F: Thrombotic microangiopathy as a complication of long-tern therapy with gemcitabine. Am. J. Kidney Dis. (1999) 33:555–562.
   PubMed Web of Science ®Google Scholar
• •Early description of gemcitabine-associated thrombotic microangiopathy.
   Google Scholar
• FUNG MC, STORNIOLO AM, NGUYEN B et al.: A review of hemolytic uremic syndrome in patients treated with gemcitabine. Cancer (1999) 85:2023–2032.
   PubMed Web of Science ®Google Scholar
• WALTER RB, JOERGER M, PESTALOZZI BC: Gemcitabine-associated hemolytic-uremic syndrome. Am. J. Kidney Dis. (2002) 40:E16.
   Google Scholar
• HUMPHREYS BD, SHARMAN JP, HENDERSON JM et al: Gemcitabine-associated thrombotic microangiopathy. Cancer (2004) 100:2664–2670.
   PubMed Web of Science ®Google Scholar
• BERENSON JR, LICHTENSTEIN A, PORTER Let al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl. I Med. (1996) 334:488–493.
   Google Scholar
• HORTBAGYI GN, THERIAULT RL, LIPTON A et al.: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. I Clin. Oncol (1998) 16:2038–2044.
   PubMed Web of Science ®Google Scholar
• Physician's Desk reference, 54th Ed., Montvale, NJ, Medical Economics Company, 2000, pp. 1998–2002
   Google Scholar
• GREEN JR, SELTENMEYER Y, JAEGGI KA, WIDLER L: Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol (1997) 80:225–230.
   PubMedGoogle Scholar
• MARKOWITZ GS, APPEL GB, FINE PL et al: Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. j Am. Soc. Nephrol (2001) 12:1164–1172.
   PubMed Web of Science ®Google Scholar
• ••Very important paper documentingFSGS due to pamidronate.
   Google Scholar
• LOCKRIDGE L, PAPAC RJ, PERAZELLA MA: Pamidronate-associated nephrotoxicity in a patient with Langerhaffs Histiocytosis. Am. J. Kidney Dis. (2002) 40:E2.
   PubMed Web of Science ®Google Scholar
• SHANKLAND SJ, EITNER F, HUDKINS KL, GOODPASTER T, D'AGATI V, ALPERS CE: Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease. Role in podocyte proliferation and maturation. Kidney [nt. (2000) 58:674–683.
   Google Scholar
• DITLOVE J, WEIDMANN P, BERNSTEIN M, MASSRY SG: Methicillin nephritis. Medicine (1977) 56:483–491.
   PubMed Web of Science ®Google Scholar
• PIRANI CL, VALERI A, D'AGATI V, APPEL GB: Renal toxicity of nonsteroidal anti-inflammatory drugs. Contr. Nephrol (1987) 55:159–175.
   PubMedGoogle Scholar
• BORDER WA, LEHMAN DH, EGAN JD, SASS HJ, GLODE JE, WILSON CB: Antitubular basement-membrane antibodies in methicillin-associated interstitial nephritis. N. Engl. J. Med. (1974) 291:381–384.
   PubMed Web of Science ®Google Scholar
• ROCHA JL, FERNANDEZ-ALONSO J: Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet (2001) 357: 1946-1947.
   Google Scholar
• ALPER AB, MELEG-SMITH S, KRANE NK: Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am. J. Kidney Dis. (2002) 40:1086–1090.
   PubMed Web of Science ®Google Scholar
• •Paper notes association of COX-2 inhibitors with both interstitial and glomerular lesions.
   Google Scholar
• HENAO J, HISAMUDDIN I, NZERUE CM, VASA\IDANI G, HEWAN-LOWE K: Celecoxib-induced acute interstitial nephritis. Am. I Kidney Dis. (2002) 39:1313–1317.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ GS, FALKOWITZ DC, ISOM R et al: Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. Chu. Nephrol (2003) 59:137–142.
   PubMed Web of Science ®Google Scholar
• BREWSTER UC, PERAZELLA MA: Acute tubulointerstitial nephritis associated with celecoxib. Nephrol Dial. Transplant. (2004) 19:1017–1018
   PubMed Web of Science ®Google Scholar
• GOLDSMITH DR, PERRY CM: Atazanavir. Drugs (2003) 63:1679–1693.
   PubMed Web of Science ®Google Scholar
• BREWSTER UC, PERAZELLA MA: Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am. J. Kidney Dis. (2004) 41:1313–1317.
   Google Scholar
• MATUSHIMA H, YONEMURA K, OHISHI K, HISHIDA A: The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J. Lab. Chu. Med. (1998) 131:518–526.
   PubMedGoogle Scholar
• TAY LK, BREGMAN CL, MASTERS BA, WILLIAMS PD: Effects of cis-diamminedichloroplatinum on rabbit kidney in vivo or rabbit renal proximaltubule cells in culture. Cancer Res. (1988) 48:2538–2543.
   PubMed Web of Science ®Google Scholar
• LEIBBRANDT MEI, WOLFGANG GHI, METZ AL, OZOBIA AA, HASKINS JR: Subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney _Lim (1995) 48:761–770.
   PubMed Web of Science ®Google Scholar
• KALOYANIDES GJ. Drug-phospholipid interactions: Role in aminoglycoside nephrotoxicity. Ren. Fail. (1992) 14:351–357.
   PubMed Web of Science ®Google Scholar
• WALKER PD, SHAH SV: Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J. OM Invest. (1988) 81:334–341.
   PubMed Web of Science ®Google Scholar
• SAWAYA BP, WEIHPRECHT H, CAMPBELL WR et al.: Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J. Clin. Invest. (1991) 87:2097–2107.
   PubMed Web of Science ®Google Scholar
• SAWAYA BP, BRIGGS JP, SCHNERMANN J: Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties. J. Am. Soc. Nephrol (1995) 6:154–164.
   PubMed Web of Science ®Google Scholar
• ROSEN LS, GORDON D, KAMIINSKI M et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A Phase III, double-blind comparative trial. Cancer J. (2001) 7:377–387.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ GS, FINE PL, STACK JI et al.: Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney _Lim (2003) 64(1):281–289.
   PubMed Web of Science ®Google Scholar
• ••Important article describing nephrotoxicity associated with zoledronate.
   Google Scholar
• SCHOOLEY RT, RUANE P, MYERS RA et al: Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS (2002) 16:1257–1263.
   PubMed Web of Science ®Google Scholar
• BARDITCH-CROVO P, DEEKS SG, COLLIER A et al: PhaseI/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2001) 45:2733–2739.
   PubMed Web of Science ®Google Scholar
• COCA S. PERAZELLA MA: Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am. J. Med. Li. (2002) 324(6):342–344.
   PubMed Web of Science ®Google Scholar
• •Early description of tenofovir-Induced ATN.
   Google Scholar
• KARRAS A. LAFAURI M. FURCO A et al: Tenofovir-related nephrotoxicity in human immunodeficiency virus infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin. Infect. Dis. (2003) 36(8): 1070–1073.
   PubMed Web of Science ®Google Scholar
• SCHAFF B. ARIES SP KRAMME E et al:Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin. Infect. Dis. (2003) e37(3):e41–e43.
   Google Scholar
• VERHELST D. MONGE M. MEYNARD JL et al.: Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am. I Kidney Dis. (2002) 40(6):1331–1333.
   Google Scholar
• RIFKIN BS, PERAZELLA MA: Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am. J. Med. (2004) 117:282–284.
   PubMed Web of Science ®Google Scholar
• HO ES, LIN DC, MENDEL DB, CIHLAR T: Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1.J. Am. Soc. Nephrol (2000) 11:383–393.
   PubMed Web of Science ®Google Scholar
• CIHLAR T, LIN DC, PRITCHARD JB, FULLER MD, Mendel DB, Sweet DH. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.Mol Pharmacol (1999) 56:570–580.
   PubMed Web of Science ®Google Scholar
• ROCH-RAMEL F: Renal transport of organic anions. Curr. Opin. Nephrol Hypertens. (1998) 7:517–524.
   PubMed Web of Science ®Google Scholar
• SWEET D, WOLFF N, PRITCHARD J: Expression cloning and characterization of ROAT1.Biol Chem. (1997) 272:30088–30095.
   Google Scholar
• ANDERSON W, BETHEA W: Renal lesions following administration of hypertonic solutions of sucrose. JAMA (1940) 114:1983–1987.
   Google Scholar
• LINDBERG H, WALD M: Renal changes following the administration of hypertonic solutions. Arch. Int. Med. (1939) 63:907–918.
   Google Scholar
• RIGDON RH, CARDWELL ES: Renal lesions following the intravenous injection of hypertonic solution of sucrose: a clinical and experimental study. Arch. _Lim Med. (1942) 69:670–690.
   Google Scholar
• DISCALA V, MAUTENR W, COHEN J, LEVITT M, CHURG J, YUNIS S: Tubular alterations produced by osmotic diuresis with mannitol. Ann. Intern. Med. (1965) 63(5):767–775.
   PubMed Web of Science ®Google Scholar
• MORGAN T, LITTLE J, EVANS W: Acute renal failure associated with low-molecular weight dextran infusion. BE Med. J. (1966) 2:737–739.
   PubMed Web of Science ®Google Scholar
• ASHP COMMISSION ON THERAPEUTICS: ASHP therapeutic guidelines for intravenous immune globulin. Chu. Pharm. (1992) 11:117–136.
   Google Scholar
• BARTON J, HERRARA G, GALLA J, BERTOLI L, WORK J, KOOPMAN W: Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am. J. Med. (1987) 82:624–629.
   PubMed Web of Science ®Google Scholar
• SCHIFFERLI J, LESKE M, FAVRE H, IMBACH P, NYDEGGER U, DAVIES K: High dose intravenous IgG treatment and renal function. Lancet (1991) 337:457–458.
   PubMed Web of Science ®Google Scholar
• ••Important paper noting association ofWIG therapy and renal failure.
   Google Scholar
• RAULT R, PIRAINO B, JOHNSTON J. ORAL A: Pulmonary and renal toxicity of intravenous immunoglobulin. Clin. Nephrol (1991) 36:83–86.
   Google Scholar
• ELLIE E, COMBE C, FERRER X: High-dose intravenous immune globulin and acute renal failure. N Engl. I Med. (1992) 327:1032–1033.
   PubMed Web of Science ®Google Scholar
• STEWART R, WINNEY R, CASH J: Renal toxicity of intravenous immunoglobulin. Vox. Sang. (1993) 65:244.
   PubMed Web of Science ®Google Scholar
• RUGGERI M, CASTAMAN G, DE NARDE G, RODEGHIERO F: Acute renal failure after high-dose intravenous immune globulin in a patient with Idiopathic Thrombocytopenic Purpura. Haematologica (1993) 78:338–339.
   PubMedGoogle Scholar
• PASATIEMPO A, KROSER J, RUDUCEK M, HOFFMAN B: Acute renal failure after intravenous immunoglobulin therapy. I Rheumatol (1994) 21:347–349.
   Web of Science ®Google Scholar
• AHSAN N, PALMER B, WHEELER D, GREENLEE R, TOTO R: Intravenous immunoglobulin-induced osmotic nephrosis. Arch. Intern. Med. (1994) 154:1985–1987.
   PubMed Web of Science ®Google Scholar
• CANTU T, HOEHN-SARIC E, BURGESS K, RACUSEN L, SCHEEL P: Acute renal failure associated with immunoglobulin therapy. Am. Kidney Dis. (1995) 25(2):228–234.
   PubMed Web of Science ®Google Scholar
• POULLIN P, MOULEN B, OLLIER J, BENARCHA M OLMER M, GABRIEL B: Hyperoncotic renal failure after intravenous immunoglobulin therapy. Presse Med. (1995) 24:441–444.
   PubMed Web of Science ®Google Scholar
• ARUNABH S, KUMAN G, AVILA V: Acute renal failure induced by intravenous immune globulin. Am. Fam. Physician (1996) 53:862–863.
   PubMed Web of Science ®Google Scholar
• CORVETTA A, DELLA BITTA R, GABRIELLA A, SPAETH PJ, DANIELLI G: Use of high dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clia Exp. Rheum. (1989) 7:295–299.
   PubMed Web of Science ®Google Scholar
• ROSTOKER G, PHILIPPON C, BELGHITTI D et al.: Intravenous IgG for glomerulonephritis and renal function. Lancet (1991) 338:544–555.
   PubMedGoogle Scholar
• KOBOSKO J, NICOL P: Renal toxicity of intravenous immunoglobulin. Clin. Nephrol (1992) 37(4):216–217.
   PubMed Web of Science ®Google Scholar
• PHILLIPS AO: Renal failure and intravenous immunoglobulin. Nephrol (1992) 37(4):217.
   Web of Science ®Google Scholar
• DONATINI B: Transient renal dysfunctionin diabetic patients after IVIG therapy. J. Int. Med. (1992) 232:376–377.
   PubMed Web of Science ®Google Scholar
• TAN E, HAJINAZARIAN M, BAY W, NEFF J, MENDELL J: Acute renal failure resulting from intravenous immmunoglobulin therapy. Arch. Neurol (1993) 50:137–139.
   PubMed Web of Science ®Google Scholar
• WINWARD DB, BROPHY MT: Acute renal failure after administration of intravenous immunoglobulin: review of the literature and case report. Pharmacotherapy (1995) 15(6):765–772.
   PubMed Web of Science ®Google Scholar
• HANSEN-SCHMIDT S, SILOMON J, KELLER F: Osmotic nephrosis due to high dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am. I Kidney Dis. (1996) 28:451–453.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN KD, SADDLER MC, TARNOVER AC, YANG G, HARFORD AM: Transient renal failure in a patient with Idiopathic Thrombocytopenic Purpura after treatment with concomitant protein-A immunosorption and intravenous immune globulin. Blood (1992) 80\(Suppl. 1):483.
   Google Scholar
• TSINALIS D, DICKENMANN M, BRUNNER F et al.: Acute renal failure in a renal allograft recipient treated with intravenous immunoglobulin. Kidney Dis. (2002) 40:667–670.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ SL, JOHNSON CB: Pinocytosis as cause of sucrose nephrosis. Nephron (1971) 8:246–254.
   PubMed Web of Science ®Google Scholar
• CAYCO AV, PERAZELLA MA, HAYSLETT JP: Renal insufficiency following intravenous immune globulin therapy: a report of two cases and analysis of the literature. J. Am. Soc. Nephrol (1997) 8:1788–1794.
   PubMed Web of Science ®Google Scholar
• LEGENDRE C, THERVET E, PAGE B et al: Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet (1993) 342:248–249.
   PubMed Web of Science ®Google Scholar
• •Initial description of osmotic nephropathy with HES.
   Google Scholar
• CITTANOVA ML, LEBANC I, LEGENDRE C et al: Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet (1996) 348:1620–1622.
   PubMed Web of Science ®Google Scholar
• DEMAN A, PEETERS P, SENNESAEL J:Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: a retrospective, multicentre analysis. Nephrol Dial. Transplant. (1999) 14:1517–1520.
   PubMed Web of Science ®Google Scholar
• BERNARD C, ALAIN M, SIMONE C et al: Hydroxyethylstarch and osmotic nephrosis-like lesions in kidney transplants. Lancet (1996) 348:1595.
   PubMed Web of Science ®Google Scholar
• LABARTHE AD, JACOBS F, BLOT F: Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. kn. J. Med. (2001) 111:417–418.
   PubMed Web of Science ®Google Scholar
• DICKENMANN MJ, FILIPOVIC M, SCHNEIDER MC, BRUNNER FP: Hydroxyethylstarch-associated transient acute renal failure after epidural anaesthesia for labour analgesia and caesarean section. Nephrol Dial. Transplant. (1998) 13:2706.
   Web of Science ®Google Scholar
• SCHORTGEN F, LACHERADE JC, BRUNNER F et al: Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet (2001) 357:911–916.
   PubMed Web of Science ®Google Scholar
• EDWARDS CA, KNOLL GA: Hydroxyethylstarch (HES) and the risk of delayed graft function (DGF) following renal transplantation. I Am. Soc. Nephrol (2002) 13:375-376A.
   Google Scholar
• WINKELMAYER WG, GLYNN RJ, LEVIN R, AVORN J: Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. Kidney Int. (2003) 64:1046–1049.
   PubMed Web of Science ®Google Scholar
• BERNS JS, COHEN RM, STUMACHER RJ, RUDNICK MR: Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. I Am. Soc. Nephrol (1991) 1:1061–1080.
   PubMed Web of Science ®Google Scholar
• FOGAZZI GB: Crystalluria: a neglected aspect of urinary sediment analysis. Nephrol Dial. Transplant (1996) 11:379–387.
   PubMed Web of Science ®Google Scholar
• PERAZELLA MA, BROWN E: Electrolyte and acid-base disorders associated with AIDS: An etiologic review. Gen. Intern. Med. (1994) 9:232–236.
   PubMed Web of Science ®Google Scholar
• ••Important review of electrolyte andacid-base disorders in HIV-infected patients. of two cases. Am. J. Kidney Dis. (1997) 30:558–560.
   Google Scholar
• GRUNKE M, VALERIUS T, MANGER B, KALDEN JR, HARRER T: Renal dysfunction in a Human Immunodeficiency Virus-infected patient who was treated with indinavir. Clin. Infect. Dis. (1997) 25:1270–1271.
   PubMed Web of Science ®Google Scholar
• GULICK R, MELLORS J, HAVLIR D et al.: Treatment with indinavir, zidovudine,
   Google Scholar
• TASHIMA KT, HOROWOTZ JD, ROSEN S: Indinavir nephropathy (letter).
   Google Scholar
• PERAZELLA MA, KASHGARIAN M, COONEY E: Indinavir nephropathy in an HIV infected patient with renal insufficiency and pyuria. Clin. Nephrol
   Google Scholar
• DAUDON M, ESTEPA L, VIARD JP, JOLY D, JUNGERS P: Urinary stones
   Google Scholar
• KOPP JB, MILLER KD, MICAN JA et al: Crystalluria and urinary tract abnormalities associated with indinavir. Ann. Intern. Med. (1997) 127:119–125.
   PubMed Web of Science ®Google Scholar
• BACH MC: Indinavir nephrolithiasis in warm climates (letter). I AIDS (1997) 14:296–297.
   Web of Science ®Google Scholar
• BERNS JS, COHEN RIVI, SILVERMAN M, TURNER J: Acute renal failure due to indinavir crystalluria and nephrolithiasis: report
   Google Scholar
• GRUNKE M, VALERIUS T, MANGER B, KALDEN JR, HARRER T: Renal dysfunction in a Human Immunodeficiency Virus-infected patient who was treated with indinavir. Clin. Infect. Dis. (1997) 25:1270–1271.
   PubMed Web of Science ®Google Scholar
• REILLY RE TRAY K, PERAZELLA MA: Indinavir nephropathy revisited: A pattern of insidious renal failure with identifiable risk factors. Am. J. Kidney Dis. (2001) 38:E23–E28.
   Google Scholar
• •Paper notes chronic kidney disease associated with indinavir and preventable risk factors.
   Google Scholar
• COHEN SM, WEXNER SD, BINDEROW SR et al: Prospective, randomized, endoscopic-blinded trial comparing precolonoscopy bowel cleansing methods. Dis. Colon Rectum. (1984) 37:689–696.
   Google Scholar
• MARKOWITZ GS, NASR SH, KLEIN P et al: Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Human Pathol (2004) 35:675-684.Important paper describing adverse effect of phosphate-containing solutions.
   Google Scholar
• ORIAS M, MAHNENSMITH RL, PERAZELLA MA: Extreme hyperphosphatemia and acute renal failure after a phosphorus-containing bowel regimen. Am. J. Nephrol (1999) 19:60–63.
   PubMed Web of Science ®Google Scholar
• DAUDON M, JUNGERS P: Drug-induced renal calculi: epidemiology, prevention and management. Drugs (2004) 64(3):245–75.
   PubMed Web of Science ®Google Scholar
• ••Outstanding and comprehensivereview of drug-induced calculi.
   Google Scholar
• WATSON RA, ETTINGER B, DESHON GE et al: Triamterene stone: advantage of crystallographic analysis. Urology (1981) 18(3):238–240
   PubMed Web of Science ®Google Scholar
• DAUDON M, BADER CA, JUNGERS P: Urinary calculi: Review of classification methods and correlations with etiology. Scanning Microsc. (1993) 7:1081–1106.
   PubMedGoogle Scholar
• NGUYEN QUY D, DAUDON M: Infrared and Raman spectra of calculi, Paris: Elsevier, 1997.
   Google Scholar